A polymeric drug delivery device is designed to provide a controlled release of a drug over an extended period of time, acting either locally or systemically.

Polymeric controlled-release systems offer a variety of benefits and opportunities to pharmaceutical companies:

- Line extension for existing drug substances.
- Brand protection through a more complex delivery system that is challenging to copy.
- High degree of convenience for patients, due to the infrequent need to remove or replace the system.
- Supply-chain savings due to the extended duration of delivery (from a month to five years) compared to tablet consumption (mostly daily).
- Lower-dose substance delivery, reducing side effects and costs).
- Differentiate a drug in competitive marketplace
- Salvage compounds shelved due to formulation difficulties
- Extend patent life (line extensions)
- Market exclusivity
- Bypass 1st pass effect

This is an exciting area with vast growth potential. QPharma has pioneered this technology and has an unparalleled track record when it comes to developing, transferring and manufacturing polymeric controlled-release systems. Our experience includes intra-vaginal rings (IVR) and intra-uterine systems (IUS) – the principles of which we are also bringing to subcutaneous implant delivery systems.

We have extensive experience in:
- Manufacturing polymeric delivery systems for over 15yrs with approval from the EU and FDA.
- Supporting development programs for Phase II onwards & clinical trials.
- Industrialisation from Phase III.
- Feasibility Studies.

New business opportunities please contact our Business Development Director.

www.qpharma.com